Ubicare Misomall.com Begins Supplying Obesity Drug "Mounjaro"

Shipping Date Moved Up by Nearly a Week Compared to Other Platforms

Ubicare, a digital healthcare platform company, announced on the 20th that it has begun supplying Eli Lilly’s “Mounjaro” through its online pharmaceutical distribution platform, Misomall.com.

Ubicare

Mounjaro is currently being shipped from Misomall.com, with the shipping date moved up by nearly a week compared to some other platforms. Orders are being processed, allowing hospital and clinic customers to receive the product more quickly than through other channels.

Misomall.com, which offers integration with Korea’s top market share EMR (Electronic Medical Record) systems “Uisarang” and “Doctors,” and distributes a wide range of essential pharmaceuticals such as IV solutions, injectables, and vaccines, has achieved more than 50% annual growth since entering the pharmaceutical distribution business in 2017.

In the second quarter of this year, transaction volume grew by 180% year-on-year, reaching an all-time high. In the first half of the year, the platform expanded direct listings from pharmaceutical companies, supplying popular products such as GC Wellbeing’s “Linaec,” JW Pharmaceutical’s “Ducray Neoptide Expert,” and Merz Korea’s “Xeomin.” In the second half, the company plans to strengthen its market presence with pre-sales of influenza vaccines and point accumulation benefits.

To mark the launch of Mounjaro, Misomall.com is holding a special promotion for non-reimbursed obesity-related injectables, which can be viewed through the featured event banner.

A Ubicare representative stated, “With the supply of Mounjaro, primary care customers now have a wider range of prescription options,” adding, “In the second half of the year, we will continue to expand our competitive pharmaceutical lineup and tailored benefits to further enhance customer satisfaction.”

This content was produced with the assistance of AI translation services.